logo-loader
HealthPharma & Biotech
Physiomics PLC

Physiomics technology to be used to analyse Bicycle Therapeutics and Cancer Research UK cancer study

The AIM-listed group’s technology will be used analyse clinical data for a CRUK-sponsored phase I/IIa clinical trial of Bicycle’s BT1718 treatment for solid tumours

virtual tumour
Physiomics is the developer of the virtual tumour software platform

Physiomics Plc (LOB:PYC), developer of the virtual tumour software platform, has landed a deal with Bicycle Therapeutics and Cancer Research UK (CRUK).

The AIM-listed group’s technology will be used analyse clinical data for a CRUK-sponsored phase I/IIa clinical trial of Bicycle’s BT1718  treatment for solid tumours.

"We are very pleased to be working on this second project with Bicycle Therapeutics and to be working for the first time directly with Cancer Research UK, the UK's leading cancer research charity,” said Physiomics chief executive, Jim Millen.

The financial details are unknown.

Quick facts: Physiomics PLC

Price: 2.75 GBX

Market: AIM
Market Cap: £1.98 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Shield Therapeutics to present data showing Feraccru offers 'real oral...

Shield Therapeutics PLC's (LON:STX) Dr Mark Sampson speaks to Proactive London's Andrew Scott ahead of them presenting positive data from the Phase 3b, open-label randomised controlled trial of Feraccru. He says the trial shows the drug, also known as Accrufer in the States, offers a real...

14 hours, 52 minutes ago

2 min read